Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer

Lichun Wu, Jie Chu, Lijuan Shangguan, Mingfei Cao, Feng LuAging 2023 · DOI

TL;DR

Researchers have identified FMO2 (Flavin-containing dimethylaniline monoxygenase 2) as a critical prognostic biomarker in breast cancer. Low expression of FMO2 correlates with significantly poorer survival outcomes, while high levels suggest a better response to modern immunotherapies, potentially acting through a co-expression axis with the tumor suppressor SFRP1.

What Problem Does This Paper Address?

Breast cancer remains the most common cancer diagnosis and the leading cause of cancer-related death among women globally. While clinical staging and hormone receptor status (ER, PR, HER2) guide treatment, there is a constant search for more precise molecular biomarkers to predict how a patient’s disease will progress and which therapies—particularly newer immunotherapies—will be most effective.

The authors focused on FMO2, an enzyme typically involved in drug metabolism. While FMO2 was known to be dysregulated in some other cancers, its specific role, prognostic value, and underlying molecular mechanisms in breast cancer were largely a "black box" until this study.

Methods

The study utilized a comprehensive bioinformatics-driven approach, integrating data from several massive public repositories. Key steps included:

  • Expression Profiling: Comparing FMO2 mRNA and protein levels in normal vs. cancerous tissues using tools like TNMplot and UALCAN.
  • Clinical Correlation: Analyzing how FMO2 levels relate to age, tumor stage, and molecular subtypes (e.g., Triple-Negative Breast Cancer).
  • Survival Analysis: Using Kaplan-Meier plots to determine the impact of FMO2 expression on Overall Survival (OS), Relapse-Free Survival (RFS), and Distant Metastasis-Free Survival (DMFS).
  • Co-expression Analysis: Identifying genes that "move" in tandem with FMO2 to find potential mechanistic partners.
  • Therapeutic Response Prediction: Using ROCplot and transcriptomic data from over 3,000 patients to see if FMO2/SFRP1 levels could predict sensitivity to chemotherapy, hormone therapy, and immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4).

Datasets

The authors validated their findings across multiple independent cohorts to ensure robustness:

  • TCGA (The Cancer Genome Atlas): Primary source for tumor/normal comparisons and clinical indicators.
  • SCAN-B (Sweden Cancerome Analysis Network - Breast): A large-scale multicenter initiative used for independent validation.
  • GTEx & TARGET: Used for pan-cancer and normal tissue baseline expression.
  • CPTAC: Provided essential proteomic (protein-level) data.
  • GEO (Gene Expression Omnibus): Sourced various gene chip and RNA-seq datasets for survival and therapy analysis.

Key Insights and Ideas

  • The FMO2-SFRP1 Connection: The most striking finding was the near-perfect correlation between FMO2 and SFRP1. While SFRP1 is a known regulator of the Wnt signaling pathway, this paper suggests the FMO2-SFRP1 axis might influence the extracellular matrix (ECM) and coagulation cascades, rather than just traditional Wnt signaling.
  • Epigenetic Silencing: The study found that SFRP1 is downregulated in breast cancer primarily due to hypermethylation of its promoter region—essentially an "off switch" added to the DNA.
  • Immunotherapy Sensitivity: Patients with high FMO2 expression were significantly more sensitive to immunotherapies like Pembrolizumab (anti-PD-1) and Atezolizumab (anti-PD-L1). This suggests FMO2 could be a "hot" tumor marker for immune-based treatments.
  • Subtype Specificity: FMO2 levels vary significantly across subtypes, being particularly low in HER2+ and Luminal B cancers, but higher in basal-like and triple-negative subtypes compared to others, though still lower than in healthy tissue.

Key Results

  • Downregulation: FMO2 is significantly lower in breast cancer tissues compared to healthy controls ($P < 0.0001$).
  • Survival Impact: Low FMO2 expression was a strong predictor of poor Overall Survival (Hazard Ratio [HR] = 0.80, $P = 0.038$) and even worse Relapse-Free Survival (HR = 0.69, $P < 0.0001$).
  • Immunotherapy Response: High FMO2 levels correlated with better OS in patients treated with anti-PD-1 therapy (HR = 0.62, $P = 0.00045$).
  • Predictive Power: SFRP1 (the co-expressed partner) was validated as a predictive biomarker for chemotherapy response (AUC = 0.578) and hormone therapy (AUC = 0.629).

Limitations and Future Work

The primary limitation is that this study is entirely computational. While the authors used multiple high-quality datasets to cross-verify their results, the "wet lab" evidence is missing.

  • Mechanistic Validation: Future research needs to perform in vitro (cell culture) and in vivo (animal model) experiments to prove that FMO2 causes these changes in tumor behavior, rather than just being a bystander.
  • Clinical Trials: Prospective clinical trials are required to determine if doctors can reliably use FMO2 levels to choose between immunotherapy and traditional chemotherapy in a real-world hospital setting.

Summary updated

Abstract

FMO2 was lower expressed in breast cancer than normal tissues and contributes to subtype classification and prognosis prediction with co-expressed SFRP1.
BibTeX
@inproceedings{wu2023discovery,
  author = {Lichun Wu and Jie Chu and Lijuan Shangguan and Mingfei Cao and Feng Lu},
  title = {{Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer}},
  booktitle = {Aging},
  year = {2023},
  doi = {10.18632/aging.205204},
}
Figure